Cannabis Bioscience International Holdings (CBIH) Cash & Equivalents (2022 - 2026)

Cannabis Bioscience International Holdings has disclosed Cash & Equivalents across 5 years of filings, most recently posting $90.0 for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $90.0, down 83.58% year-over-year; the trailing twelve-month figure through Feb 2026 was $90.0 (down 83.58% YoY), and the FY2025 annual result was $12952.0, up 1615.5% from the prior year.
• Cash & Equivalents came in at $90.0 for Q1 2026 at Cannabis Bioscience International Holdings, down from $132.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $25655.0 in Q1 2023 to a low of $90.0 in Q1 2026.
• The 5-year median for Cash & Equivalents is $881.5 (2024), against an average of $5800.4.
• Across the five-year window, Cash & Equivalents tumbled 98.6% in 2023 and soared 1615.5% in 2025, its largest moves.
• Cannabis Bioscience International Holdings' Cash & Equivalents stood at $24089.0 in 2022, then plunged by 98.6% to $337.0 in 2023, then jumped by 197.33% to $1002.0 in 2024, then sank by 86.83% to $132.0 in 2025, then sank by 31.82% to $90.0 in 2026.
• The last three Cash & Equivalents figures came in at $90.0 (Q1 2026), $132.0 (Q4 2025), and $223.0 (Q3 2025), per Business Quant data.